Company intelligence / Profile preview

AB2 Bio Ltd.

Lausanne, Vaud, Switzerlandab2bio.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 3

Overview

AB2 Bio has completed Phase 3 trials for Tadekinig alfa in North America and Europe and is preparing for submission of a Biologics License Application (BLA) in the U.S. The drug has received Orphan Drug Designation, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Designation in Europe.

Therapeutic areas: ImmunologyRare DiseasesRheumatology
Modalities: Recombinant protein (Tadekinig alfa is a recombinant human IL-18 binding protein)
Industry: Biotech

Drug pipeline

2 assets

tadekinig alfa

1 more asset in the full pipeline.

Request access →

Partnerships

Nippon Shinyaku (licensing agreement for U.S. commercialization of Tadekinig alfa)WuXi Biologics (manufacturing collaboration)

Beyond the preview

Go deeper on AB2 Bio Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AB2 Bio Ltd..

Explore the full profile